Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

✍ Scribed by Taal, Walter; Oosterkamp, Hendrika M; Walenkamp, Annemiek M E; Dubbink, Hendrikus J; Beerepoot, Laurens V; Hanse, Monique C J; Buter, Jan; Honkoop, Aafke H; Boerman, Dolf; de Vos, Filip Y F; Dinjens, Winand N M; Enting, Roelien H; Taphoorn, Martin J B; van den Berkmortel, Franchette W P J; Jansen, Rob L H; Brandsma, Dieta; Bromberg, Jacoline E C; van Heuvel, Irene; Vernhout, René M; van der Holt, Bronno; van den Bent, Martin J

• Book ID: 125828313
• Publisher: The Lancet
• Year: 2014
• Tongue: English
• Weight: 358 KB
• Volume: 15
• Category: Article
• ISSN: 1470-2045
• DOI: 10.1016/S1470-2045(14)70314-6